Ann: Board and Management Restructure, page-105

First 105 Last

Share
Profile

Follow
Lowkeyinvestor

4,253 Posts.

1512

05/06/22

20:28

Post #: 61831258
Share

Originally posted by Lowkeyinvestor: ↑

Hi Zonnald,

I have seen that Directors interest disclosure.

But it is a disclosure and not an issue of shares advice.

The 5,000,000 employee options were allotted 0n 19/5/20. It is in the annual report.

I have not seen a Directors interest disclosure when 4,156,205 shares were divested from his 33,000,000 allotment on Longland aquisition.

Did he get additional 5,000,000 employee options as a NED (as a non employee) expiring on the same date 30 September 2024. I don't think so.

Markyboy49 fell out with me after I questioned TAJ appointment as a non employee NED. Thats all there is to it.

I respect MB49 analysis and I am sorry that my posts have upset him, I'd rather he come back to the forum. I know I go over the top at times and have been moderated a number of times and suspended for weeks, but that just me. I mean no malice to anyone and I am a bit like a dog with a bone.

In my long ago former employ I was a Chartered Secretary (technically qualified) and I have loosely kept up to date with that profession. I now the ins and outs of board meetings and director appointments.

All my opinion and no malice intended.

Expand

Actually the number of shares sold was 4,485,146 off a base issue of 33,328,795.

ASX list rule Continuous Disclosure - 3.19A.2 basically requires individual directors to disclose transactions within 5 days (not the company).

My question is what date were the shares sold. Were they sold during the season in Greenland and at what price?

CNJ Price at posting: 3.7¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 63 more messages in this thread...

First 105 Last

Add CNJ (ASX) to my watchlist

(20min delay)
Last 0.1¢		Change 0.000(0.00%)		Mkt cap ! $2.201M

Open	High	Low	Value	Volume
0.1¢	0.1¢	0.1¢	$2.5K	2.5M

Buyers (Bids)

No.	Vol.	Price($)
1	3053031	0.1¢

Sellers (Offers)

Price($)	Vol.	No.
0.2¢	80159825	58

View Market Depth

No.	Vol.	Price($)
1	3053031	0.001
0	0	0.000
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.002	80159825	58
0.003	8380418	9
0.004	3005000	5
0.005	2500000	2
0.006	300000	1

Last trade - 13.11pm 07/10/2024 (20 minute delay)

CNJ (ASX) Chart

Ann: Board and Management Restructure, page-105

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Board and Management Restructure, page-105

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News